J&J rallies near record highs as investors seek defensive cover
+1.04% to $273.04 from $270.24
What moved JNJ
- Johnson & Johnson shares advanced as investors rotated into defensive healthcare names during the broader technology selloff.
- The move builds on J&J’s second-quarter results, in which sales rose 6.6% to $25.3 billion and adjusted EPS reached $2.90.
- The company tightened its 2026 guidance, pointing to full-year revenue surpassing $100 billion for the first time.
- Shares traded just below the stock’s Aug. 19 record closing high, up about 29% since the start of the year.
Sources: Yahoo Finance · Ad Hoc News